Prostate Cancer | Specialty

Monitoring Advanced Prostate Cancer: Next-Gen Imaging

October 12th 2017

Metastatic Prostate Cancer: Testing for BRCA Mutations

October 12th 2017

The Impact of DNA Repair Defects on Prostate Cancer

October 12th 2017

Metastatic Prostate Cancer: Intrinsic Genomic Subtypes

October 12th 2017

Metastatic Prostate Cancer: Androgen Receptor Biology

October 12th 2017

The Underlying Biology of Metastatic Prostate Cancer

October 12th 2017

Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

October 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.

FDA Approval Sought for Apalutamide in Prostate Cancer

October 11th 2017

A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).

Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance

October 10th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

Precision Medicine Has Emerging Role in mCRPC

October 6th 2017

Andrew J. Armstrong, MD, discusses emerging treatments and techniques for precision medicine in metastatic castration-resistant prostate cancer.

Novel Imaging Techniques Advancing Prostate Cancer Care

October 5th 2017

William R. Berry, MD, discusses luteinizing hormone-releasing hormone agonists versus antagonists as treatment options for patients and highlights the novel techniques for prostate cancer imaging.

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

October 4th 2017

Tian Zhang, MD, discusses emerging results for patients with metastatic castration-sensitive prostate cancer.

Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

October 3rd 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Expert Discusses Optimizing Sequence of Non-Hormonal Therapy in mCRPC

October 3rd 2017

Daniel J. George, MD, discusses the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer

September 29th 2017

Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

September 27th 2017

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

Pivotal Role Remains With Bone-Targeting Agents in mCRPC

September 27th 2017

Charles Ryan, MD, discusses the evolution of zoledronic acid and denosumab, and the future role of radium-223 as it begins to be studied in combination regimens in prostate cancer.

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

September 26th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Expert Talks Optimizing ADT in Prostate Cancer

September 22nd 2017

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Use of Active Surveillance Increasing for Low-Risk Prostate Cancer

September 21st 2017

Matthew R. Cooperberg, MD, discusses the benefits associated with active surveillance for patients with low-risk prostate cancer, as well as the development of personalized medicine.